About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Colorado | 18,143 Studies Near You | Clareo Health

Clinical Trials LocationsColorado

Clinical Trials in Colorado

Discover 18,143 clinical trials near Colorado. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11881-11900 of 18,143 trials

COMPLETEDPhase 131 miles

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

NCT02960854

A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.

Bristol-Myers Squibb38 participantsStarted Dec 2016

Sacramento, California, United States • Colorado Springs, Colorado, United States • Denver, Colorado, United States +13 more locations

COMPLETEDPhase 244 miles

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

NCT02669433

This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.

Dementia With Lewy Bodies

Axovant Sciences Ltd.484 participantsStarted Jan 2016

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Sun City, Arizona, United States +62 more locations

Find Trials by Condition in Colorado

Breast Cancerin Colorado Lung Cancerin Colorado Prostate Cancerin Colorado Colorectal Cancerin Colorado Melanomain Colorado Leukemiain Colorado Lymphomain Colorado Pancreatic Cancerin Colorado Ovarian Cancerin Colorado Brain Cancerin Colorado Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 346 miles

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147197

This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids

LeiomyomaUterine Hemorrhage

Allergan157 participantsStarted Mar 2014

Tucson, Arizona, United States • San Diego, California, United States • Denver, Colorado, United States +25 more locations

COMPLETEDNA50 miles

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625

Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases. Scientific investigation of this issue has been quite complicated, primarily because the use of respirators has become "the standard of care" for protection against airborne diseases in some instances, even without sufficient evidence to support their use. The key question remains: How well do respirators prevent airborne infectious diseases? The answer to this important question has important medical, public health, political and economic implications.

InfluenzaRespiratory Syncytial VirusesParamyxoviridae Infections+2 more

Johns Hopkins University2,862 participantsStarted Dec 2010

Aurora, Colorado, United States • Denver, Colorado, United States • Denver, Colorado, United States +4 more locations

COMPLETEDPhase 450 miles

The Effect of Tablet Size on Cognitive Performance Caffeine

NCT03694886

This study aims to assess if tablet size, due to placebo effect, alters participants' performance on cognitive tests after consuming caffeine. Participants will be randomly assigned to one of four groups: 1) 90 mg caffeine with a 1 mm diameter sucrose pillule; 2) no caffeine with the small sucrose pillule; 3) 90 mg caffeine with a 5 mm sucrose pillule; 4) no caffeine with the large sucrose pillule.

University of Colorado, Denver120 participantsStarted Oct 2018

Denver, Colorado, United States

COMPLETEDNA53 miles

Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback

NCT01333189

The purpose of this study is to determine if rehabilitation using weight-bearing biofeedback training following total knee arthroplasty (TKA) is more effective than standard rehabilitation methods in promoting weight-bearing symmetry through the lower limbs during functional activities such as sit-to-stand transfers and walking. Secondary outcomes of interest include functional measures and internal moment at the hip, knee, and ankle joints during sit-to-stand and walking.

Arthropathy of Knee Joint

University of Colorado, Denver26 participantsStarted Jan 2011

Aurora, Colorado, United States

COMPLETED53 miles

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

NCT02588053

Primary Aims: To determine how effective long term Natalizumab (NTZ) therapy is in slowing the progression of whole brain atrophy. Whole brain atrophy rates will be measured through magnetic resonance imaging (MRI) scans and compared between patients with Multiple Sclerosis (MS) who have been using NTZ for at least 2 years versus age and gender-matched healthy controls. The primary outcome will be whole brain atrophy rate measured as the percent change in brain volume (PBVC) over a two-year period. Primary hypothesis: The investigators hypothesize that long term (\>2 years) NTZ therapy will slow the rate of whole brain atrophy in patients with Multiple Sclerosis (MS) (as measured by percent change in brain volume), reaching a whole brain atrophy rate similar to that of non-MS controls (a true "disease activity free" state).

Multiple Sclerosis

University of Colorado, Denver85 participantsStarted Jul 2014

Aurora, Colorado, United States

WITHDRAWNPhase 153 miles

Antepartum Etonogestrel Contraceptive Implant Insertion at Term

NCT03656289

Short-interval pregnancy (SIP) or rapid, repeat pregnancy is defined as a pregnancy within one year of prior delivery. These pregnancies are often unintended and are associated with adverse risks. Low contraceptive initiation during the postpartum period is a contributing factor to SIP. This study will be the first to investigate the initiation of a highly-effective, immediately active contraceptive device during the antepartum period. The antepartum period serves as an ideal time for postpartum contraception counseling, due to patients' active involvement with the healthcare system. The pharmacokinetic analysis proposed in this study will be the first to investigate whether and to what extent ENG hormone crosses the placenta. This data will enrich understanding of the pharmacology of exogenous progestins administered during pregnancy and provide information that can be incorporated into future patient counseling regarding the risks of fetal exposure with exogenous progestin use.

University of Colorado, DenverStarted Jan 2019

Aurora, Colorado, United States

COMPLETED106 miles

10003 PRO Current Products

NCT01497730

This post-marketing investigation will evaluate the functional knee performance of Subjects who have undergone primary total knee arthroplasty (TKA). Data from Subjects who receive one of four contemporary knee configurations from different manufacturers will be pooled to establish a contemporary dataset. The primary objective of this study is to evaluate the functional performance as measured by the activities of daily living (ADL) sub-score of the Knee Osteoarthritis Outcomes Score (KOOS) patient-reported outcome (PRO) questionnaire of primary TKA at minimum one year post-operation. This will be carried out for all four implant configurations. The final endpoint is a 2-year evaluation.

DePuy Orthopaedics842 participantsStarted Oct 2011

Orange, California, United States • San Diego, California, United States • Fort Collins, Colorado, United States +19 more locations

TERMINATEDPhase 2284 miles

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

NCT01467076

This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure (NHRF). Fifty patients recruited at 10 high volume sites within the NICHD Neonatal Research Network will constitute a pilot sample to evaluate the feasibility and safety of prolonged IPGE1 administration and determination of optimal dose. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours and compared with placebo. Once feasibility and safety of IPGE1 administered over 72 hours has been demonstrated in the pilot trial, a full scale randomized controlled trial will be planned.

PrematurityRespiratory InsufficiencyPulmonary Hypertension+1 more

NICHD Neonatal Research Network7 participantsStarted Nov 2011

Birmingham, Alabama, United States • Los Angeles, California, United States • Palo Alto, California, United States +8 more locations

COMPLETEDPhase 3368 miles

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

NCT01994889

This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.

Transthyretin (TTR) Amyloid Cardiomyopathy

Pfizer441 participantsStarted Dec 2013

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +77 more locations

COMPLETEDPhase 3517 miles

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

NCT01211873

The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.

Diagnostic Self EvaluationCentral Nervous System Diseases

Guerbet416 participantsStarted Sep 2010

Birmingham, Alabama, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +49 more locations

COMPLETEDPhase 2/3530 miles

MEmbranous Nephropathy Trial Of Rituximab

NCT01180036

The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.

Idiopathic Membranous Nephropathy

Mayo Clinic130 participantsStarted Nov 2011

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +18 more locations

TERMINATEDPhase 2540 miles

Sorafenib for Hepatopulmonary Syndrome

NCT02021929

The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.

Hepatopulmonary Syndrome

University of Pennsylvania28 participantsStarted Mar 2014

Phoenix, Arizona, United States • Chicago, Illinois, United States • Rochester, Minnesota, United States +4 more locations

COMPLETED573 miles

Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

NCT02446587

SELECT is a multicenter, observational prospective study implementing a protocol to acquire imaging and clinical variables known to affect clinical outcomes after endovascular therapy in an effort to evaluate and compare the different selection methods and criteria currently used in practice for acute ischemic stroke patients in the anterior circulation with large vessel occlusion. The study aim is to evaluate prospectively different selection methodologies for endovascular therapy, to compare them against each other to identify which method provides the highest predictive ability in the selection of patients for IAT and to devise a formula that predicts patients' outcomes. This study will enroll patients based on the recent AHA guidelines (July 2015) regarding treatment of patients with acute ischemic strokes and large artery occlusions in the anterior circulation. Our goal is to collect complete imaging, clinical, and 90 day follow up data on 250 endovascular therapy patients as well as up to 250 concurrent medical management patients as a comparison group.

StrokeIschemic Stroke

The University of Texas Health Science Center, Houston500 participantsStarted Jan 2016

Stanford, California, United States • Orlando, Florida, United States • Atlanta, Georgia, United States +6 more locations

COMPLETEDNA744 miles

Dissonance Eating Disorder Prevention: Clinician Led, Peer Led vs Web Delivered

NCT01949649

Five percent of young women meet criteria for anorexia nervosa, bulimia nervosa, or binge eating disorder, with another 5% meeting criteria for Eating Disorder Not Otherwise Specified (ED-NOS), which includes subthreshold variants of these disorders. Over half of those presenting for eating disorder treatment meet criteria for ED-NOS and both threshold cases and ED-NOS are marked by chronicity, relapse, distress, functional impairment, and increased risk for future obesity, depression, suicide attempts, anxiety disorders, substance abuse, morbidity, and mortality. Anorexia and bulimia nervosa show stronger relations to suicide attempts, outpatient/inpatient treatment, and functional impairment than most other psychiatric disorders. Treatment of eating disorders is very expensive, similar to the cost for schizophrenia treatment, and is effective for only 40-60% of patients. Thus, a public health priority is to develop and disseminate effective eating disorder prevention programs.

Eating Disorder Prevention

Oregon Research Institute680 participantsStarted Apr 2013

Corvallis, Oregon, United States • Eugene, Oregon, United States • Austin, Texas, United States

COMPLETEDPhase 1780 miles

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

NCT01877811

This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid tumors with specific histologies and/or molecular alterations of interest. Patients in Phase 1b will be treated at the RP2D determined in Phase 1.

Hoffmann-La Roche143 participantsStarted Jun 2013

Duarte, California, United States • Irvine, California, United States • San Diego, California, United States +11 more locations

COMPLETEDPhase 3796 miles

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519

A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.

Overactive BladderUrinary Incontinence

Allergan356 participantsStarted Mar 2013

Newport Beach, California, United States • Leuven, Belgium • Vancouver, British Columbia, Canada +5 more locations

COMPLETEDPhase 4856 miles

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

NCT00131469

The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI).

Osteogenesis Imperfecta

Oregon Health and Science University79 participantsStarted Jun 2005

Baltimore, Maryland, United States • Portland, Oregon, United States • Houston, Texas, United States

COMPLETEDPhase 2/3991 miles

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function

NCT01723696

Vitamin C supplementation (500 mg per day) given to pregnant women who can not quit smoking will improve the pulmonary function tests in their offspring measured at 3 months of age.

Pulmonary Function; Newborn, AbnormalInfant WheezeIn-utero Nicotine+1 more

Oregon Health and Science University252 participantsStarted Dec 2012

Indianapolis, Indiana, United States • Portland, Oregon, United States

PreviousPage 595 of 908Next

in Colorado

Heart Diseasein Colorado